Bicara Therapeutics price to book ratio BCAX
Market value divided by the book value of the company's net assets, since 2024.
- Today, Nov 2, 2026
- 1.1×
- Peer median
- 2.0×
Bicara Therapeutics' price to book ratio is 1.1× as of Nov 2, 2026.
The median for 10 large drugmakers of a similar size is 2.0×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.1× | 1.1× | 3.9× |
| 2025 | 2.3× | 1.0× | 2.5× |
| 2024 | 2.0× | 1.9× | 2.3× |
Against its peers
Companies in Drug Manufacturers - General nearest Bicara Therapeutics' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| BCAXBicara Therapeutics | 1.1× |
| PBYIPuma Biotechnology | 3.8× |
| ARVNArvinas | 0.9× |
| IRWDIronwood Pharmaceuticals | n/m |
| ZVRAZevra Therapeutics | 2.8× |
| CRMDCorMedix | 0.9× |
| COLLCollegium Pharmaceutical | 2.5× |
| ABUSArbutus Biopharma | 3.1× |
| AMPHAmphastar Pharmaceuticals | 1.5× |
| OMEROmeros | n/m |
| NATRNatures Sunshine Products | 1.2× |
| Peer median | 2.0× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Bicara Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.